Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This is a pilot study of adjuvant therapy for patients with leiomyosarcoma of the uterus that
has been completely removed by surgery. "Adjuvant" therapy means that the tumor (the
leiomyosarcoma) has been completely removed by surgery; thus, giving further treatment now is
done in hopes of decreasing the chance that the tumor will come back (relapse or recur). The
main goal of this study is to show that this series of treatments is safe for patients with
your type of tumor.
In this trial you will be getting drugs that have been approved for use in some types of
cancer. In this study we wish to see whether the combination of two chemotherapy drugs,
docetaxel and gemcitabine can decrease the chance of your tumor, leiomyosarcoma of the
uterus, from coming back (relapsing). We will also be looking at the short-term side effects
and risks of the drugs given in this combination to patients with leiomyosarcoma that has
been completely resected (removed by surgery).
The combination of gemcitabine and docetaxel has been shown to be safe, and it has been shown
to decrease the size of leiomyosarcoma tumors in patients with leiomyosarcoma of the uterus
that has relapsed, or has continued to grow despite treatment with other chemotherapy drugs.